TY - JOUR
T1 - Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
AU - Malecek, Mary Kate
AU - Watkins, Marcus P.
AU - Bartlett, Nancy L.
N1 - Funding Information:
N Bartlett is supported in part by the Foundation for Barnes-Jewish Hospital, obtained research funding from ADC Therapeutics, Autolus, Bristol-Meyers Squibb, Celgene, Forty Seven, Genentech, Gilead, Janssen, Kite Pharma, Millennium, Novartis, Pfizer, Pharmacyclics, Seattle Genetics and has served on the advisory board for Acerta, ADC Therapeutics, Kite, and Seattle Genetics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: Polatuzumab vedotin is an antibody–drug conjugate comprised of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin (MMAE), a microtubule-disrupting cytotoxin. CD79b is almost exclusively expressed on normal and malignant B-cells, making it an appealing target for novel therapeutics. Areas covered: This article reviews the current literature on polatuzumab vedotin, including its pharmacology, as well as summarizing the results of clinical trials in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as a single agent and in combination with other chemotherapies and chemoimmunotherapies. The current landscape of approved therapies for relapsed and refractory DLBCL, as well as other promising novel approaches, is discussed. Expert opinion: The recent approval of polatuzumab vedotin in combination with bendamustine and rituximab (BR) offers another option to patients with DLBCL who are not eligible for autologous hematopoietic cell transplant or chimeric antigen receptors (CAR)-T cell therapy. In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
AB - Introduction: Polatuzumab vedotin is an antibody–drug conjugate comprised of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin (MMAE), a microtubule-disrupting cytotoxin. CD79b is almost exclusively expressed on normal and malignant B-cells, making it an appealing target for novel therapeutics. Areas covered: This article reviews the current literature on polatuzumab vedotin, including its pharmacology, as well as summarizing the results of clinical trials in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as a single agent and in combination with other chemotherapies and chemoimmunotherapies. The current landscape of approved therapies for relapsed and refractory DLBCL, as well as other promising novel approaches, is discussed. Expert opinion: The recent approval of polatuzumab vedotin in combination with bendamustine and rituximab (BR) offers another option to patients with DLBCL who are not eligible for autologous hematopoietic cell transplant or chimeric antigen receptors (CAR)-T cell therapy. In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
KW - CD79b
KW - Diffuse large B cell lymphoma
KW - antibody-drug conjugate
KW - polatuzumab vedotin
UR - http://www.scopus.com/inward/record.url?scp=85087115666&partnerID=8YFLogxK
U2 - 10.1080/14712598.2020.1777979
DO - 10.1080/14712598.2020.1777979
M3 - Article
C2 - 32500753
AN - SCOPUS:85087115666
SN - 1471-2598
VL - 21
SP - 831
EP - 839
JO - Expert opinion on biological therapy
JF - Expert opinion on biological therapy
IS - 7
ER -